Anti-B7-H3 antibody

A B7-H3, antibody technology, applied in the direction of antibodies, antibody medical components, anti-tumor drugs, etc., can solve problems such as changes in antibody performance

Active Publication Date: 2014-03-26
DAIICHI SANKYO CO LTD
View PDF14 Cites 33 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Although antibodies are specific for the same antigen, antibod...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-B7-H3 antibody
  • Anti-B7-H3 antibody
  • Anti-B7-H3 antibody

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0181] 2. Preparation of anti-B7-H3 antibody

[0182] The anti-B7-H3 antibody of the present invention can be obtained as follows: According to a conventional method, an animal is immunized with B7-H3 or any polypeptide selected from the amino acid sequence of B7-H3, and the antibody produced in the body is collected and purified. The biological species of B7-H3 used as an antigen is not limited to humans, and B7-H3 derived from animals other than humans such as mice or rats can be used to immunize animals. In this case, by testing the cross-reactivity between the antibody and the obtained binding of heterologous B7-H3 and human B7-H3, an antibody suitable for human diseases can be selected.

[0183] In addition, according to known methods (for example, Kohler and Milstein, Nature, (1975) 256, pages 495-497; Kennet, R. Ed., Monoclonal Antibody, pages 365-367, Prenum Press, NY (1980)) , Monoclonal antibodies can be obtained by fusing antibody-producing cells producing anti-B7-H3 an...

Embodiment 1

[0350] Example 1. Preparation of plasmid

[0351] 1)-1 Preparation of human B7-H3 expression vector

[0352] 1)-1-1 Preparation of expression vector of full-length human B7-H3 variant 1

[0353] Using cDNA synthesized from the total RNA of LNCaP cells (American Type Culture Collection (ATCC)) as a template, and also using the following primer set, a PCR reaction was performed, thereby amplifying cDNA encoding human B7-H3 variant 1 :

[0354] Primer 1:

[0355] 5'-ctatagggagacccaagctggctagcatgctgcgtcggcggggcag-3' (SEQ ID NO: 1 in the sequence listing); and

[0356] Primer 2:

[0357] 5'-aacgggccctctagactcgagcggccgctcaggctatttcttgtccatcatcttctttgctgtcag-3' (SEQ ID NO: 2 in the Sequence Listing).

[0358] Subsequently, using MagExtractor PCR & Gel cleanup (TOYOBO, Co., Ltd.), the PCR product thus obtained was purified. Then, the PCR product was digested with restriction enzymes (NheI and NotI), and then purified using MagExtractor PCR & Gel cleanup (TOYOBO, Co., Ltd.). The pcDNA3.1(+) plas...

Embodiment 2

[0419] Example 2. Preparation of monoclonal antibodies and screening of antibodies

[0420] 2)-1 Immunization

[0421] BALB / cAnNCrlCrlj mice (Charles River Laboratories Japan, Inc.), FcgRII KO mice (Taconic, Inc., IBL Co., Ltd.) or GANP mice (Transgenic, Inc.) aged 4-6 weeks were used. On days 0, 7, 15 and 24, 5 x 10 6 At a dose of 1 cell / mouse, LNCaP cells, MCF7 cells (ATCC) or AsPC1 cells (ATCC) detached with ethylenediaminetetraacetic acid (Invitrogen Corporation) were subcutaneously administered to the back area of ​​each mouse. On the 31st day, take 5 x 10 6 The dose of one cell, the same cell was administered intravenously to each mouse. On day 34, the spleen was excised from each mouse and used to prepare hybridomas.

[0422] 2)-2 Preparation of hybridoma

[0423] Using PEG 4000 (manufactured by IBL Co., Ltd.), spleen cells and mouse myeloma P3X63Ag8U.1 cells (ATCC) were subjected to cell fusion, thereby preparing hybridomas.

[0424] As a result, the following clones were est...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to an antibody which has a therapeutic effect on tumors. Namely, the present invention relates to an antibody which binds to B7-H3 and exhibits antitumor activity. The objective of the present invention is to provide a pharmaceutical product which has a therapeutic effect on tumors. An anti-B7-H3 antibody which binds to B7-H3 and exhibits antitumor activity is obtained, and a pharmaceutical product for treating tumors, which contains the antibody, or the like is obtained.

Description

Technical field [0001] The present invention relates to an antibody that binds to B7-H3 and can be used as a therapeutic and / or preventive agent for tumors, and also relates to a method of using the antibody to treat and / or prevent tumors. Background technique [0002] B7-H3 is a protein with a single-pass transmembrane structure (Non-Patent Document 1). The N-terminal extracellular domain of B7-H3 contains 2 variants. Variant 1 contains V-like and C-like Ig domains at each of the 2 sites, respectively, and variant 2 contains V-like and C-like Ig domains at 1 site, respectively . The C-terminal intracellular domain of B7-H3 contains 45 amino acids. [0003] TLT-2 having a single-pass transmembrane structure has been reported as a receptor for B7-H3 (Non-Patent Document 2). However, it is also reported that TLT-2 is not a receptor for B7-H3 (Non-Patent Document 3). According to the previous report, when the receptor binds to B7-H3, it enhances the activation of CD8-positive T c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/09A61K38/00A61K39/395A61P35/00C07K16/28C12N1/15C12N1/19C12N1/21C12N5/10C12N15/02C12P21/02C12P21/08
CPCC07K16/30C07K2317/732C07K16/2827C07K16/42C07K2317/734C07K2317/24C07K2317/73A61P35/00C07K16/28A61K39/395A61K39/39558A61K45/06A61K2039/505C07K2317/40C07K2317/92
Inventor 高桥秀松冈达司村上贤二泷泽刚广谷贤志浦野敦司福地圭介矢泽光弘
Owner DAIICHI SANKYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap